JCR Pharmaceuticals said on July 28 that it has filed its human growth hormone agent Growject (somatropin) for an additional indication of short stature due to short stature homeobox-containing gene (SHOX) deficiency. The submission is based on a Japan PIII…
To read the full story
Related Article
- JCR Launches PIII Study of Growject for SHOX Deficiency
July 3, 2018
- Growject to Enter PIII Study for SHOX Deficiency: JCR
May 21, 2018
BUSINESS
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





